- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Sustainable Track Record
Hong Kong Pharmaceuticals & Biotech Sustainable Track Record
Results
3
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
3 companies
HBM Holdings
Market Cap: HK$11.7b
A biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally.
2142
HK$14.73
7D
9.9%
1Y
1,169.8%
Consun Pharmaceutical Group
Market Cap: HK$12.3b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$14.90
7D
3.3%
1Y
165.1%
Shanghai Henlius Biotech
Market Cap: HK$41.8b
Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
2696
HK$77.00
7D
-8.2%
1Y
231.9%